Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

Opinion|Videos|September 19, 2024

COBRA AND PROPELLER: Background and Results of Prior PSMA Imaging Trials

Author(s)Michael Gorin, MD

Michael Gorin, MD provides the background and results of two key imaging trials that reviewed the efficacy of this new copper-based agent.

Episodes in this series

EP. 1 PSMA PET Imaging: The Landscape and Current Challenges

EP. 1 PSMA PET Imaging: The Landscape and Current Challenges

EP. 2 Emerging Copper-Based Developments in PSMA Imaging

EP. 2 Emerging Copper-Based Developments in PSMA Imaging

EP. 3 COBRA AND PROPELLER: Background and Results of Prior PSMA Imaging Trials

EP. 3 COBRA AND PROPELLER: Background and Results of Prior PSMA Imaging Trials

EP. 4 The CLARIFY Trial Design and Objectives for PSMA Imaging

EP. 4 The CLARIFY Trial Design and Objectives for PSMA Imaging

EP. 5 Potential Impact of Forthcoming CLARIFY Trial Results

EP. 5 Potential Impact of Forthcoming CLARIFY Trial Results

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Latest CME

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Trending on Urology Times

The ArteraAI Prostate Test: What It Is and How It Works

HHS requests testosterone therapy label updates, citing new safety data

Retrospective study suggests differences in OAB therapy persistence among older adults

Sandip Prasad, MD, highlights 3-year data on mitomycin for intravesical solution for LG-IR-NMIBC

FDA gives nod to feasibility study of NanoKnife IRE for benign prostatic hyperplasia